SRC and pancreatic neoplasm: Dasatinib (N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide; BMS-354825, Sprycel), a tyrosine kinase inhibitor originally developed against BCR-ABL and SRC [4] and currently used in the treatment of CML [5] and Philadelphia chromosome-positive acute lymphoblastic leukemia (reviewed in [6]), has also shown promise in the treatment of various epithelial tumours [6] including pancreatic cancer.